secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001558370-24-010370
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics cuts 80% workforce, begins strategic review after FDA setback for uproleselan
--------------------------------------------------------------------------------

- FDA feedback requires an additional clinical trial for uproleselan in R/R AML; regulatory path uncertain.
- Workforce reduced by 26 employees (~80%); expects $3.6M in severance charges in Q3 2024.
- CMO Dr. Edwin Rock departs July 31; will receive 12 months' base salary severance and consulting deal.
- Cash and equivalents ~$31.3M as of March 31; restructuring extends cash runway into Q2 2025.
- Engaged Lucid Capital Markets to explore strategic alternatives including sale, merger, or licensing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837024010370/0001558370-24-010370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837024010370/glyc-20240724x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-010370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer